文献速递妇科

OTL38注射剂用于叶酸受体α阳性卵巢癌术中成像的II期多中心开放标签试验

A phase II, multicenter, open-label trial of OTL38 injection for the intra-operative imaging of folate receptor-alpha positive ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2019-07-27

这项前瞻性II期多中心开放标签试验评估OTL38近红外成像在卵巢癌细胞减灭术中的安全性和有效性。44例患者评估安全性,29例患者225个病灶评估疗效,不考虑患者内相关性时灵敏度85.93%、阳性预测值88.14%,控制相关性后分别为97.97%和94.93%。48.3%(14/29)患者经OTL38单独检出至少一个额外病灶,8例发生轻度药物相关不良事件,结论认为OTL38近红外成像安全有效,值得III期评估。

要点

  • 不考虑患者内病灶相关性时,OTL38近红外成像灵敏度85.93%、阳性预测值88.14%。
  • 控制患者内病灶检测相关性后,灵敏度97.97%、阳性预测值94.93%。
  • 48.3%(14/29)患者经OTL38单独检出至少一个额外病灶,8例发生轻度药物相关不良事件。

核心结论

  • OTL38近红外成像在这项II期研究中安全有效,且不受叶酸表达水平影响,值得进行III期评估。

研究设计与样本

  • 前瞻性II期多中心开放标签试验,疑似卵巢癌计划行细胞减灭术的患者接受OTL38,近红外成像由两名盲法病理学家评估。
  • 44例患者评估安全性;29例患者的225个病灶(改良意向治疗人群)评估疗效,该人群为接受OTL38近红外成像、接受手术且至少有一个叶酸受体α阳性靶病灶的患者。
  • 采用两种广义线性模型(含和不含随机效应)估计灵敏度和阳性预测值。

主要发现

  • 不考虑患者内病灶间相关性时,灵敏度估计为85.93%(95%置信区间下限=81.19),阳性预测值估计为88.14%(95%置信区间下限=83.59)。
  • 控制单个患者内多个病灶检测的实际相关性(随机效应)后,灵敏度估计为97.97%(95%置信区间下限=87.75),阳性预测值估计为94.93%(95%置信区间下限=86.13)。
  • 48.3%[14/29(95%置信区间0.29-0.67)]的患者经OTL38单独检出至少一个额外病灶。
  • 8例患者发生轻度药物相关不良事件,包括输注反应、恶心、呕吐和腹痛。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: OTL38 is a folate-indole-cyanine green-like conjugate to folate receptor alpha (FRa). The objectives of this prospective trial were to assess the safety and efficacy (sensitivity and positive predictive value (PPV)) of OTL38 for intraoperative imaging during epithelial ovarian cancer surgery. METHODS: Patients with suspected ovarian cancer planned for cytoreductive surgery were eligible to receive OTL38. Near-infrared (NIR) imaging was used to visualize target lesions that were evaluated by two blinded pathologists. A modified intent to treat (mITT) population of lesions from all patients who received OTL38-NIR imaging, underwent surgery, and had at least one FRa + target lesion was used to determine sensitivity and PPV. Two generalized linear models, with and without random effects, were employed to estimate sensitivity and PPV. RESULTS: Forty-four patients were evaluated for safety, and 225 lesions from 29 patients (the mITT population) were evaluated for efficacy. When assuming no correlation of interlesional results within a patient, sensitivity was estimated at 85.93% (95% lower boundary CI = 81.19) and PPV at 88.14% (95% lower boundary CI = 83.59). When controlling for actual correlation of detection among multiple lesions within a single patient (a random effect), sensitivity was estimated at 97.97% (95% lower boundary CI = 87.75) and PPV at 94.93% (95% lower boundary CI = 86.13). A total of 48.3% [14/29, (95% CI 0.29-0.67)] of patients had at least one additional lesion detected by OTL38 alone. Eight patients had mild drug-related adverse events including infusion reaction, nausea, vomiting, and abdominal pain. CONCLUSIONS: OTL38-NIR was safe and efficacious in this phase II study regardless of folate expression levels and merits phase III evaluation.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Randall LM, Wenham RM, Low PS, et al. A phase II, multicenter, open-label trial of OTL38 injection for the intra-operative imaging of folate receptor-alpha positive ovarian cancer. Gynecol Oncol. 2019. PMID: 31362825. doi:10.1016/j.ygyno.2019.07.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。